Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study have?
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study has 794 citations in the OpenAlex counts ScholarIQ stores.
When was Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study published?
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study has 2018 year in the ScholarIQ index.
What is the open-access status of Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study?
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study has closed oa status in the ScholarIQ index.
What is the DOI of Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study?
The DOI for Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study is on the source record.
What is the PMID of Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study?
The PMID for Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study is on the source record.
What is the OpenAlex record for Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study?
The OpenAlex for Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study is on the source record.